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Mucosal surfaces are prominent in the gastrointestinal, urogenital, and respiratory tracts 
and provide portals of entry for pathogens. The mucosal immune system consists of 
molecules, cells, and organised lymphoid structures intended to provide immunity to 
pathogens that impinge upon mucosal surfaces. The aim of this study was to assess 
humoral immunity in the vaginal mucosa and compare this immune response to a systemic 
response. 
The use of commercially available tampons provided a self-administered, pain free method 
for the collection of vaginal secretions. To standardise specimens, a total protein 
determination was performed on vaginal secretions and on sera. All subjects were screened 
for sexually transmitted infections (STIs) using conventional and deoxyribonucleic acid 
(DNA) amplification tests. Immunoglobulin levels in vaginal secretions and in sera were 
quantitated using a quantitative sandwich enzyme- linked- immunosorbent assay (ELISA). 
The immunoglobulin levels quantitated were analysed on the basis of pregnancy status and 
the presence or absence of an STI. Immunoglobulin results for serum showed a significant 
increase in IgG and IgA in women with an STI regardless of pregnancy (p< 0.001). This 
study showed a decrease in vaginal IgG and IgA in women with an STI. Non-pregnant 
women with an STI had significantly lower levels of IgG and IgA in the cervico-vaginal 
secretions as compared to the controls (p=0.002 and p=0.0002 respectively). This was also 
observed in pregnant women (p= 0.03 and p< 0.001 respectively). IgM levels were mostly 
too low to be detectable but showed a tendency to increase in vaginal secretions of women 
with an STI. Pregnancy did not have an effect on immunoglobulin levels except for IgA. 
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The effects observed were due to the presence of an STI. All the STI pathogens studied 
displayed a similar effect on immunoglobulin levels. Bacterial vaginosis, however, appears 
to exert an effect specifically on lowering IgG (p=0.008) in vaginal fluid and increasing 
IgG levels (p=0.008) in serum. 
Once a more complete understanding of the mechanisms associated with the host defence 
of the vaginal mucosa is obtained, specific immunotherapeutic strategies can be developed. 
A greater knowledge of host defence factors specific to the vagina will provide insights 
into understanding susceptibility to opportunistic infections and STIs. 
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It has long been known that the presence of antibody (Ab) in local secretions correlates 
better with protection against pathogenic organisms than serum Ab. Tomasi and Hanson 
discovered in 1968 that the major Ab in external secretions was immunoglobulin A (IgA) 
in a unique secretory configuration (secretory IgA; slgA). With this came the belief that 
slgA was responsible for immune protection of mucosal surfaces (Ernst et ah, 1987). 
While it is still true that IgA remains the best marker of local mucosal responses, other 
humoral and cellular mechanisms must also be considered in the assessment of mucosal 
resistance. Very little is known about the immunological mechanisms functioning at the 
vaginal mucosa, and much of what is known comes from animal studies rather than human 
data (Fidel and Sobel, 1996). 
Establishing precise correlates for mucosal protection against genital tract pathogens by the 
humoral immune system requires quantitative information about specific antibody 
concentrations in genital tract secretions. The most convenient and widely used method for 
collection of such secretions from the female genital tract is cervical-vaginal lavage (Belec 
et ah, 1995). However, this sampling technique results in a considerable and non-
standardised dilution of the secretions and this may render antibody concentrations too low 
and non-comparable to be detected by available assays. It should also be noted that the 
amount of secretion varies between women and over time which would cause the 
concentration of the immunoglobulins to vary due to changing dilution factors. 
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Furthermore, lavage samples cannot provide quantitative information about the 
concentrations of antibodies or immunoglobulin isotypes present on mucosal surfaces at 
specific locations in the genital tract (Quesnel e. ah, 1997). A study aimed at collecting 
secretions from specific sites in the vagina was carried out by Quesnel et al. (1997) using 
Sno-strips (Akorn Inc., Abita Springs LA). The method utilizes absorbent filter strips that 
are placed at a specific site to collect secretions, however, the Sno-strips are pliable and 
difficult to handle, while mucus adheres without being absorbed. 
Therefore, we applied a method of specimen collection using commercially available 
tampons that can be self-administered and are easy to use. With this method the amount of 
material collected cannot be standardized and therefore the dilution factor varies. The 
introduction of the immunoglobulin/ total protein ratio overcomes this problem. 
3 
CHAPTER TWO 
2.0 LITERATURE REVIEW 
2.1 Mucosa-associated lymphoid tissue (MALT) 
Mucous membranes have a specialized immune system which is evident from the 
extensive studies on the gastrointestinal-associated lymphoid tissue (GALT) (Ernst et al, 
1987). All mucosal surfaces are protected by similar systems termed "mucosa-associated 
lymphoid tissue" (MALT). MALT arose from the realisation that not only did mucosal 
surfaces share organisational similarities in their lymphoid elements, but also functional 
ones (Bienenstock et al, 1978). MALT is characterised by the predominance of local IgA 
production and by the finding that activated lymphocytes derived from one mucosal 
surface can recirculate and localise selectively to other mucosal surfaces. 
2.2 Vaginal Mucosa 
The wall of the vagina consists of three layers: the mucosa, the muscular coat and the 
adventitial connective tissue. The mucosa consists of a surface epithelium and an 
underlying lamina propria. The vaginal epithelium is made up of stratified squamous 
epithelium (Fig la) 150 to 200 |J.m in thickness, consisting of about 45 layers of cells 
during the follicular phase of the cycle and about 30 in the luteal phase (Bloom and 
Fawcett, 1986). The cytoplasm in the superficial cells is filled with glycogen, especially at 
midcycle. In pregnancy, the vaginal mucosa becomes thicker, th# vaginal muscle 
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hypertrophies and there is an alteration in the composition of the surrounding connective 
tissue (Llewellyn- Jones, 1999). 
Superficial cells are continually shed from the surface of the vaginal epithelium throughout 
the cycle, but this desquamation is greater late in the luteal phase and during menstruation. 
During pregnancy there is an increased desquamation of the superficial vaginal mucosal 
cells with increased vaginal discharge. These changes are initiated by oestrogen and occur 
early in pregnancy (Llewellyn-Jones, 1999). 
The amount of glycogen in the epithelium is controlled by oestrogen, the pH of the vaginal 
fluid is lowest at midcycle (Bloom and Fawcett, 1986, Kerr, 1999). Glycogen from the 
exfoliated cells is a rich substrate for Lactobacilli, which break it down to lactic acid, 
lowering the pH of the vagina (Mims et al, 1999). During pregnancy there is an increase 
in oestrogen production, which reduces the vaginal pH substantially. 
The vagina is devoid of glands and goblet cells and much of the lubricating fluid is 
contributed by secretions from mucin secreting columnar epithelial cells of the cervix 
(Coombs et ah, 2003). It is generally agreed, however, that there is true vaginal fluid that 
increases in abundance during sexual stimulation. Therefore fluid collected from the 
vagina is best referred to as cervico-vaginal secretions. The intercellular spaces of the 
epithelium are accessible to mononuclear leukocytes. Lymphocytes normally breach the 
basal lamina, open the desmosomes and invade the enlarged intercellular spaces (Bloom 
and Fawcett, 1986). Accumulation of lymphocytes is numerous, and sometimes lymph 
nodules are present (Bloom and Fawcett, 1986). A well developed system of lymph vessels 
is present in the wall of the vagina (Bailey, 1978). It has been shown that the vaginal 
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epithelium includes a population of Langerhans cells, which appears as scattered clear cells 
occupying expanded intercellular channels in its basal and intermediate layers. 
The lamina propria is a moderately dense connective tissue (Fig lb). Immediately under 
the epithelium there is a dense network of fine elastic fibres. From there, fine fibres run 
downward to the muscular layer. The deeper layers of the lamina propria contain a dense 
plexus of small veins (Fig li). 
The muscular coat is made up predominantly of longitudinal (Fig If) and obliquely 
arranged bundles of muscle fibres (Fig lh) and the interstitial connective tissue is rich in 
elastic fibers (Bailey, 1982). 
The adventitial coat (Fig lg) is a thin layer of dense connective tissue, which merges into 
the loose connective tissue joining the vagina to the surrounding structures. In this 
connective tissue, an extensive venous plexus, nerve bundles and small groups of nerve 
cells can be found (Bloom and Fawcett, 1986). Vaginal tissues receive blood supply from 
uterine arteries and sometimes branches of the internal iliac artery. Blood returns to the 
venous system through veins that empty into the internal iliac veins. Lymphatic drainage is 
via the external and internal iliac lymph nodes and superficial inguinal lymph nodes 
(Bloom and Fawcett, 1986). 
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Figure 1. Haemotoxylin- eosin stain (30 X) of the human vagina, longitudinal 
Section (Di Fiore, 1974). 
a- stratified squamous epithelium 
b- papillae in the superficial layer of the lamina propria 
c- lymphocyte nodule 
d- lamina propria 
e- folds of the mucosa 
f- longitudinal bundles of smooth muscle fibers 
g- adventitia 
h- oblique bundles of smooth muscle fibers 
i- veins and artery 
j - tranverse bundles of smooth muscle fibers 
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2.3 Host Defense 
2.3.1 Non- specific Mechanisms 
2.3.1.1 Mucous Membranes 
Mucous membranes are the surfaces that line the gastrointestinal, the respiratory, and the 
urogenital tract. Mucous membranes comprise one or more layers of living cells and are 
constantly moist as a result of the secretion and absorption of chemical substances (Salyers 
and Whitt, 1994). This provides a warm wet environment, which is readily colonized by 
normal vaginal flora. Colonisation is allowed when this involves useful, non-pathogenic 
organisms that do not interfere with the primary function of the mucosal membrane. 
Protection against colonisation with harmful, pathogenic organisms is provided by a 
number of defences. 
Goblet cells (which produce mucus), M (microfold) cells (which aid in the presentation of 
antigens to underlying cells of the immune system) and ciliated cells (which propel 
fragments of mucus away from the area) perform a protective function. In addition the 
secreting or absorbing cells perform the basic physiological functions of the membrane. 
2.3.1.2 Mucosal Barrier 
2.3.1.2.1 Mucous Coat 
The vaginal mucous membrane is covered by a layer of mucus (or mucin), which provides 
an important protective function. Mucus is a thick, sticky substance composed of 
polysaccharides and proteins, secreted by goblet cells. Mucus acts as a lubricant that 
prevents any particulate matter from damaging the delicate cell layers that form the 
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mucous membrane. It also functions as a physical barrier that traps bacteria before they can 
reach the membrane itself. The adhesive property of mucous is due in part to the fact that it 
contains carbohydrate structures similar to the ones on mucosal cells. Bacteria that can 
adhere to mucosal cell surface carbohydrates will also adhere to mucus and will thus be 
prevented from attaching to mucosal cells (Salyers and Whitt, 1994). 
Mucus contains an antibody called secretory immunoglobulin A (slgA). One part of slgA 
binds to antigens on the bacterial surface and another part (the Fc portion) binds to mucin 
components, thus contributing to the ability of mucin to trap bacteria (Kato and Owen, 
1994). Blobs of mucus containing trapped bacteria are expelled by either peristalsis or 
ciliated cells that propel them away from the site. 
The mucin layer is often but not always depicted as a homogenous layer of constant 
thickness. Streams of mucus emerging from the goblet cells create layers of mucus 
separated by areas of lower viscosity (Salyers and Whitt, 1994). The continued expulsion 
of mucus blobs creates areas of uneven thickness. Bacteria may be able to take advantage 
of the non-homogenous nature of the mucin layer by moving along planes of low viscosity 
to reach mucosal cells (Salyers and Whitt, 1994). 
2.3.1.2.2 Mucosal Shedding 
Bacteria that manage to colonize the surface of the mucous membranes are prevented from 
passing through this membrane by tight junctions between the mucosal cells. Few, if any, 
bacteria are capable of disrupting tight junctions and crossing the membrane by moving 
between cells (Salyers and Whitt, 1994). 
9 
Bacteria that succeed in reaching and adhering to mucosal cells also have to cope with the 
rapid turnover of mucosal cells. Mucosal cells are among the most rapidly dividing 
populations of cells in the body and are constantly being produced and released from the 
membrane. Bacteria that manage to attach themselves to mucosal cells would be expelled 
from the membrane as the cells are released and must thus be able to divide and reattach 
rapidly enough to remain at the site. 
2.3.1.3 Innate Humoral Factors 
In addition to acting as a physical barrier, mucus also contains substances that either kill 
bacteria or inhibit their growth. Innate humoral factors are products that are secreted onto 
mucosal surfaces by exocrine glands and are able to carry out protective functions 
independently of the presence of specific antibodies. 
These factors include lysozyme and lactoferrin (Kato and Owen, 1994). Lysozyme is an 
enzyme that degrades bacterial peptidoglycan. It is effective mainly against gram-positive 
bacteria because the peptidoglycan of gram-negative is protected by their outer membrane 
(Tramont and Hoover, 2000). 
Lactoferrin is a protein that binds iron with a high affinity. Iron is essential for bacterial 
growth. Most bacteria are unable to compete with lactoferrin for free iron. Thus, lactoferrin 
reduces the amount of iron available for bacterial growth (Weinberg, 2001). However, 
effective pathogens such as Neisseria gonorrhoeae produce substances that can compete 
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As lymphoid aggregates similar to Peyer's patches are found in the female genital mucosa, 
it can be assumed that similar processes occur at this site. This suggests the existence of a 
relatively independent compartmentalised immune response in the female genitalia. 
13 
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Figure 2: Interaction between M cells, macrophages as APCs, T-helper 
cells and B- cells leading to the production of secretory IgA 
at the site of infection. 
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2.4.2 Efferent Arm of MALT 
2.4.2.1 Humoral Immunity 
The role of IgG and IgM in the protection of mucosal surfaces is incompletely understood. 
They are not transported nearly as efficiently as IgA into the mucosal secretions, and they 
are not as resistant to proteolysis. 
2.4.2.1.1 IgA 
IgA, discovered by Heremans (Heremans et al, 1959), was shown to exist in the unique 
form of secretory IgA as the predominant immunoglobulin in external respiratory and 
gastrointestinal tract secretions (Chordirker and Tomasi, 1963; Tomasi et al, 1965). The 
predominance of IgA in mucosal secretions is thought to be the result of the collection of 
IgA-selective regulatory T cells (Croitoru and Bienenstock, 1994). IgA- committed cells 
form part of a recirculating pool that may be stimulated locally to produce antibody or may 
have emigrated from a distant site where they were previously primed by antigen. 
Once IgA is secreted by mucosal plasma cells in the lamina propria, it is selectively 
transported across the mucosal epithelium to function in the external secretions. The 
selective secretion of IgA is promoted by certain structural features of this immunoglobulin 
that allow it to bind to a specific transport receptor termed the secretory component (SC) in 
the basal membrane of the epithelial cell (Ernst et al., 1987). This then results in 
endocytosis and transcytosis to the apical membrane (Brandtzaeg et al, 1988) (Fig 3). 
The mechanism of transport of IgA is one of the best examples of the non-degradative 
transcellular transport of proteins through cells. Secretory component, which mediates the 
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transport of IgA, is a protein expressed as an integral membrane protein on the basolateral 
membrane of mucosal epithelial cells. This receptor is apparently continuously 
endocytized and transported across the epithelial cell and secreted at the apical membrane 
into the mucosal secretions. The transport of IgA occurs following its synthesis and 
secretion by plasma cells in the lamina propria. IgA binds with high affinity to SC on the 
epithelial cell and is transported to the mucosal secretion bound to its receptor in the form 
of a complex (SC-IgA). Mucosal secretions therefore contain a mixture of secretory IgA 
and free SC (Ernst et ah, 1987). 
Secretory IgA appears to have unique properties that may explain its predominance at the 
mucosal surface. Both the dimeric nature and the addition of SC confer on secretory IgA 
considerable resistance to proteolysis. IgA is more resistant to proteolytic degradation than 
IgG or monomeric IgA (Shuster, 1971; Underdo wn and Dorrington, 1974). IgA does not 
activate complement via the classical pathway and, therefore, tends not to induce 
potentially damaging inflammatory reactions (Colten and Bienenstock, 1974) but functions 
to neutralise toxins and viruses (Ogra et ah, 1968; Holmgren et ah, 1975) and to prevent 
bacterial adherence to epithelial cells (Williams and Gibbons, 1972). IgA antibodies may 
exert their microbial function primarily by binding to antigenic epitopes on 
microorganisms. This binding restricts their mobility or prevents their binding to mucosal 
epithelium 
It has also been claimed that slgA may perform antibody-dependent cell-mediated 
cytotxicity and promotes phagocytosis via Fca receptors on various cell types (Brandtzaeg 
etah, 1987). 
16 






LUMINAL UH BILE CANALICULAR SURFACE 
Figure 3. Model for transport of IgA and IgM across the mucosal cell.(Tomasi, 1994). 
1-synthesis and core glycosylation of SC. 
2-processing and terminal glycosylation in Golgi complex. 
3-expression of receptor and complexing with polymeric IgA or IgM. 
4-endocytosis of ligand- receptor complexes and unoccupied receptor. 
5-transcytosis from basolateral to luminal surface. 
6-exocytosis of slgA and IgM and free SC. 
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2.4.2.1.2 IgM 
IgM is a pentamer with a single J chain and makes up 10% of immunoglobulins in sera 
(Nairn, 2001). In the primary immune response IgM is the major immunoglobulin 
involved. IgM has five units linked by disulphide bonds giving it ten antigen binding sites 
and is therefore far more effective in agglutination (Nairn, 2001). Due to its five Fc 
portions, IgM is also more effective at activating complement (Nairn, 2001). 
IgM in the external secretions also is associated with SC, which results from its transport to 
the secretions by SC (Braendtzaeg, 1985). Secretory IgM has been shown to follow the 
same intracellular route through secretory epithelia as slgA. However the concentration of 
secretory IgM is substantially lower than that of secretory IgA because of the lower 
proportion of IgM-producing cells in mucosal tissue. 
2.4.2.1.3 IgG 
IgG is a monomelic immunoglobulin and makes up 75% of serum immunoglobulins 
(Nairn, 2001). Because of its small size (150 OOODa), IgG is the only immunoglobulin that 
crosses the placenta (Nairn, 2001). IgG protects the newborn for about 6-9 months. There 
are 4 major subclasses of IgG, IgGl; IgG2; IgG3 and IgG4 (Rassanti and Kipps, 1997). 
IgG is best at opsonizing bacteria but is less effective at activating complement than IgM. 
Intra- and extravascular spaces are evenly distributed with IgG and IgG is the major 
antibody involved in the secondary immune response (Rassanti and Kipps, 1997). 
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In most species, the concentration of IgG in mucosal secretions is approximately the same 
as or somewhat greater than that of IgM. IgG is thought to enter the mucosal secretions 
non-specifically via paracellular transport or fluid phase endocytosis. 
2.4.2.2 Cell Mediated Immunity in the Female Genital Tract 
Technological advances in the ability to identify cells in mucosal tissue have revealed that 
the vaginal mucosa of mice contains large numbers of, dendritic- like Langerhans cells, 
macrophages, and T-cells. Vaginal Langerhans cells are major histocompatibility complex 
(MHC) class II dendritic-like cells capable of antigen presentation in the vaginal 
submucosa (Fidel and Sobel, 1996). Intraepithelial lymphocytes in the submucosa are 
capable of migrating towards the epithelial surface or into the uterine lumen in response to 
chemotactic factors (Fidel and Sobel, 1996). Thus, the presence of T-cells and antigen-
presenting cells suggests that the vaginal mucosa may be an immunocompetent tissue 
capable of a cell mediated immune response (Fidel and Sobel, 1996). 
This, together with the fact that the vaginal epithelium is permeable to proteins with 
different molecular weights, suggests that antigens present in the vaginal lumen could gain 
access to Langerhans cells, which could in turn stimulate resident T lymphocytes (Fidel 
and Sobel, 1996). This hypothesis is supported by studies performed in animal models of 
genital Chlamydia trachomatis infections, in which vaginal lymphocytes from infected 
animals were found to proliferate and produce cytokines in response to chlamydial 
antigens (Igietseme and Rank, 1991; Cain and Rank, 1995). Epithelial cells were originally 
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thought to be immunologically inert. However, epithelial cells can be induced to express 
MHC class II antigens and thus play a role in antigen presentation (Fidel and Sobel, 1996). 
T lymphocytes found in the vaginal mucosa have been described as phenotypically distinct 
from those in the periphery (Fidel and Sobel, 1996). It has been shown that although T-
cells expressing the CD4 or CD8 receptor have been identified in the murine vaginal 
mucosa, lymphocytes isolated from the vaginal tissue of naive mice and analysed by flow 
cytometry contained few CD8 cells, resulting in a high CD4/ CD8 cell ratio, and that CD4 
cells did not recognise some epitope-distinct anti-CD4 antibodies normally recognised by 
peripheral T-cells (Fidel et al, 1996). These observations suggest a different distribution or 
migration of lymphocytes within the vaginal mucosa and a possible atypical expression of 
the CD4 receptor on vaginal CD4 cells compared with T-cells in the periphery or at other 
mucosal sites (Fidel and Sobel, 1996). 
2.5 Site Specific Variations In Immunoglobulin Output 
Waldman et. al. (1971) found that secretory IgA was the predominant (-45%) 
immunoglobulin class in normal cervicovaginal secretions, the remainder consisting 
mainly of monomeric IgA (-20%) and IgG (-30%). Others have reported predominance of 
IgG also in normal vaginal fluid, mainly existing as intact molecules (Hocini et al, 1995). 
Several studies have shown that both IgA and IgG are present in cervico- vaginal fluids 
and that IgG appears to be the predominant immunoglobulin, but the reported ratios of IgG 
to IgA vary from approximately 2:1 to 10:1 (Chordirker and Tomasi, 1963; Masson et al, 
1969; Schumacher, 1973, 1980; Tjokronegoro and Sirisinha, 1975; Coughlan and Skinner, 
20 
1977; Jalanti and Isliker, 1977; Usala et al, 1989). A recent study by Bard et. al. (2002) 
compared the rates of immunoglobulins in genital fluids and found a higher IgG 
prevalence (80%) in cervico- vaginal and endocervical secretions than IgA (12%). 
This fits with a detailed study showing considerable variations, with IgA dominating in 
mucous from the endocervix and less so ectocervix, and IgG dominating in vaginal fluid 
(Quesnel et al., 1997). Measurements of immunoglobulins in human uterine fluid also 
indicate that IgG is the predominant immunoglobulin present (Schumacher et al, 1979). 
Nevertheless the uterus may be the primary source of IgA in cervico- vaginal fluids, since 
the concentration of IgA in vaginal fluid from hysterectomized women was only about 
10% of normal (Jalanti and Isliker, 1977). 
When interpreting these observations one has to keep in mind that specimen collection 
methods can be responsible for differences in observations, in particular when absolute 
quantities are inferred. 
2.6 Influences on Mucosal Immune Reactivity 
2.6.1 Resident Microflora 
Resident microflora are known to co-exist within the intestinal tract and maintain a stable 
environment by precluding attachment of enteropathogens. The flora can eliminate foreign 
pathogens by producing antimicrobial substances (colicins, short chain fatty acids), 
(Iglewski and Gerhardt, 1978; Byrne and Dankert, 1979) and by stimulating the growth of 
mucosal epithelium (Thompson and Trexler, 1971). 
21 
The vaginal tract is normally colonized by a complex resident microflora that probably 
plays an important protective role. It consists of a complex mixture of gram- positive and 
gram-negative bacteria. The vagina is predominantly colonised by species from the genus 
Lactobacillus, a genus of lactic acid producing gram-positive bacteria. It has been 
suggested that lactobacilli help to prevent pathogens from colonizing the vagina by 
keeping the pH low (around 4.5) by the production of hydrogen peroxide (Klebanoff et al., 
1991), and by forming a biofilm that prevents pathogens from gaining access to the 
mucosal surface of the vagina or cervix, but other members of the microflora probably also 
contribute to protection of the site. 
2.6.2 Endocrine Regulation 
The secretion of IgG and IgA antibodies into vaginal fluids was shown to be reduced in the 
presence of high levels of estrogen (Schumacher, 1980). In vitro studies similarly showed 
that antigen presentation of ovalbumin to cloned lymph node cells by cells isolated from 
the vaginal mucosa (presumably Langerhans cells) was inhibited by estradiol (Wira et al., 
1994). The addition of progesterone reversed the inhibitory effect (Wira and Rossoll, 
1995). 
In a study by Wira et al. (1994) it was found that the uterine response was specific for 
estradiol, that progesterone blocks estradiol-stimulated increases in uterine IgA and IgG. 
However, progesterone either alone or with estradiol decreases cervico- vaginal levels of 
IgA and IgG. It was also found that when estradiol was given to ovariectomised rats, SC 
levels increased sharply, in parallel with IgA in uterine secretions (Sullivan et al, 1983). In 
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contrast, SC levels in cervico- vaginal secretions were reduced markedly in response to 
estradiol treatment (Wira and Sullivan, 1985). 
2.7 Sexually Transmitted Infections (STIs) 
Sexually transmitted agents have long been recognised to be responsible for many acute 
genital infections, but only recently has a wider role been established for these agents in 
the epidemiology of maternal and infant morbidity and mortality. Although men can have 
long term complications from STIs, they are often more symptomatic early in the infection 
cycle and thus may seek care before the infection becomes deeply established. Women, on 
the other hand, are more susceptible to infection and may be asymptomatic in the early 
stages of infection. Thus, they may be less likely to seek health care and more likely to 
transmit disease to other sexual partners. 
In addition to causing widespread infections, STIs have a major impact on reproductive 
health; infertility has been linked to some genital infections (e.g. Chlamydia and 
Mycoplasma species) and maternal-fetal transmission of genital organisms remains a 
common cause of fetal and infant morbidity and mortality (Moodley and Sturm, 2000). 
The most common non- ulcerative STIs in sub-Saharan Africa are discussed below. 
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2.7.1 Gonorrhoea 
Gonorrhea is an infectious disease primarily involving the genitourinary tract. Members of 
the genus Neisseria are gram-negative rods or cocci, represented by more than fifteen 
species (Knapps, 1988). Gonorrhoea is caused by the small gram- negative diplococcus 
Neisseria gonorrhoeae, an extracellular parasite whose only natural host is humans. 
Transmission is most commonly by sexual contact, and infection usually occurs in the 
more sexually active age groups. Severe infection involving the eyes can develop in the 
newborn that becomes infected during passage through the birth canal. 
The acute disease is manifested by a urethritis, usually purulent in nature, in the male and 
may or may not be associated with symptoms of urethritis or vaginal discharge in the 
female. Approximately 30- 50 % of females colonised with N. gonorrhoea are 
asymptomatic (Youmans et al., 1985; Sturm et ah, 1998). In woman the complications due 
to infections are more prevalent as patients are often unaware of their infection. Ascending 
infection involving the fallopian tubes and ovaries may result in pelvic inflammatory 
disease, which produces a chronic, debilitating infection that can cause partial or complete 
obliteration of the patency of the fallopian tubes. 
As in most mucosal infections, the function of local antibody is thought to be prevention of 
attachment and subsequent infection of the host mucosa (Mestecky and McGhee, 1987). 
Urethral exudates from men with gonococcal infection have demonstrated that all three 
antibody classes (IgA, IgG and IgM) are produced in response to infection (Kearns et al., 
1973; McMillan et al, 1979a). In women, vaginal washings after infection with gonococci 
have been shown to contain both IgG and IgA antibodies against pili, lipopolysaccharide 
(LPS), and the outer membrane proteins (OMPs) implicated in attachment (Lammel et al, 
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1985; Ison et ah, 1986). Although IgA and IgG specific for gonococci have been 
demonstrated, production of specific IgM has not been well documented (O'Reilly et al, 
1976; McMillan et al, 1979b; Ison et al, 1986). Despite the formation of these antibodies, 
little is known about their functional activity. Rapid re- infection (Moodley et al, 2002) 
indicates that its protective effect is limited. 
2.7.2 Chlamydiae 
Long classified as large viruses due to their size (200-400 nm in diameter) and their 
intracellular parasitism (Schacter and Dawson, 1979; Ward, 1983), chlamydia organisms 
are now considered as a special type of bacteria. Recent studies have shown chlamydia to 
have both ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) as well as a cell wall 
similar in structure and chemical content to that of bacteria. Chlamydiae are intracellular 
parasites in that they are incapable of synthesising adenosine triphosphate (ATP) and are 
dependent on the host cell for energy and as a source of metabolism (Moulder, 1984; Cook 
and Honeybourne, 1994). Multiplication occurs by binary fission and in contrast to viruses, 
chlamydiae are susceptible to antibiotics. 
Chlamydia trachomatis is a major cause of genital tract infections in humans. Although it 
is well established that chlamydiae are associated with infectious urethritis in males, 
culture for Chlamydia trachomatis from females with mucopurulent cervicitis has shown a 
carriage rate of approximately 20 percent (Youmans et al., 1985). This finding suggests 
that the cervix is the primary site of infection in the female. 
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The antibody response to C. trachomatis has been well documented (Rank et al, 1979; 
Monnickendam and Pearce, 1983; Schachter et al, 1983; Monnickendam, 1988). Although 
humoral antibodies are generated in C. trachomatis infection (IgM, IgG and IgA), their 
role in subsequent protection is partial or transitory, at best (Katz et al, 1987; Rank et al, 
1988). 
2.7.3 Bacterial Vaginosis (BV) 
Bacterial vaginosis, previously known as nonspecific vaginitis or Gardnerella vaginitis, is 
the most common cause of vaginal discharge. It may be the cause of up to one half of cases 
of vaginitis (Eschenbach et al, 1988) in all women and the cause of from 10 to 30 percent 
of cases in pregnant women (Colli et al, 1996). The local prevalence of BV among 
pregnant women was found to be 21% (Sturm et al, 2002). 
This clinical syndrome is now recognised as a polymicrobial event involving a loss of the 
normal lactobacilli and an overgrowth of anaerobes. The pathogen of this condition is still 
obscure. While commonly found in increased numbers in women with bacterial vaginosis, 
Gardnerella vaginalis is not invariably present. G. vaginalis has been reported in 16 to 42 
percent of women with no signs or symptoms of vaginitis (Hill, 1993) and G. vaginalis is 
now accepted as just one of the BV associated organisms. 
BV is associated with an increased risk of several pathologic conditions, including adverse 
outcome of pregnancy (Hillier et al, 1990), pelvic inflammatory disease (Eschenbach et 
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ah, 1988), postpartum endometritis (Watts et ah, 1990), urinary tract infections (Sturm, 
1989; Hughes and Hillier 1990) and vaginal cuff cellulitis (Soper et.al, 1990). 
Bacterial vaginosis is diagnosed by the presence of three of the following clinical and 
microscopic findings viz. homogenous vaginal discharge (colour and amount may vary), 
presence of clue cells (greater than 20%), amine (fishy) odour when potassium hydroxide 
solution is added to vaginal secretions, vaginal pH greater than 4.5 and the absence of the 
normal vaginal lactobacilli (Majeroni, 1998). 
Some controversy remains over the sexual transmission of bacterial vaginosis. While it 
occurs more commonly in women with more than one sexual partner, bacterial vaginosis 
can also occur in women who are not yet sexually active (Bump and Buesching, 1988). 
Treatment of male partners has not resulted in improved cure rates or a reduced rate of 
recurrence (Moi et ah, 1989). 
2.7.4 Trichomoniasis 
Trichomonas vaginalis is the cause of one of the most common sexually transmitted 
diseases, trichomoniasis (Draper et al., 1993). T. vaginalis is a pathogenic protozoan which 
resides only in the lower genitourinary tract of human beings, its only natural host. 
Worldwide, the World Health Organisation estimates that 180 million persons are infected 
annually. 
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Trichomoniasis is transmitted sexually and both males and females may be infected. 
Persons infected with T. vaginalis may not show any signs of infection, thus one of the 
difficulties encountered in any study of T. vaginalis is asymptomatic carriage (Hammil, 
1989). The appearance of symptoms may be influenced by local immune factors and 
inoculum size. Vaginal discharge is found in more than half of symptomatic cases. 
T. vaginalis activates the alternative complement pathway (Shaio et al, 1991) and attracts 
polymorphonuclear neutrophils (Shaio et al, 1992) which can kill the protozoans (Rein et 
al, 1980). On the other hand T. vaginalis moves away from the products of 
polymorphonuclear neutrophil oxidative metabolism (Styrt et al, 1991). Monocytes and 
macrophages can also kill trichomonads in vitro, but their role in natural infection is 
uncertain (Mantovanic et al, 1991). Local and systemic humoral responses and delayed 
hypersensitivity are seen in human infection (Alderete et al, 1991) but they have 
insufficient sensitivity and specificity to permit serologic diagnosis. Whether these 
immune responses confer any protection is currently uncertain. 
2.8 Immunization and Immune Regulation 
After MALT B and T cells at a particular site have been stimulated by an antigen, most of 
them remain in the area and continue to produce IgA locally, but some migrate to other 
mucosal surfaces and produce IgA there. Thus, exposure of one mucous membrane to a 
bacterial pathogen results in production of slgA at other mucosal surfaces and in breast 
milk (Ernsts, al, 1987). 
Although the urogenital tract apparently lacks classical organized MALT structures, the 
squamous epithelium of the vagina and ectocervix contains MHC class Il-positive putative 
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antigen presenting cells (APCs) of the Langerhans type (Bjercke et al, 1983; Wira and 
Rossoll, 1995). Furthermore, there is experimental evidence in rodents to suggest that 
uterine MHC class Il-positive stromal and epithelial cells may perform antigen 
presentation (Wira and Rossoll, 1995). Such cells are also present in the human 
endometrium, and candidate APCs occur in the cervical and vaginal stroma as well (White 
et al, 1997). This may explain why topical antigen application together with mucosal 
adjuvant induces a prominent vaginal IgG response in mice (Menge et al, 1993). 
Substantial dissemination of primed immune cells from GALT to exocrine effector sites 
beyond the gut is the rationale for many desired oral vaccines (Mestecky et al, 1994; 
Staats et al, 1994). Oral vaccines work by stimulating the MALT of the gastrointestinal 
tract directly. The secondary migration of MALT T and B cells to other mucosal surfaces 
spreads immune protection to these other areas (Fig 4). 
A preferential link between nasal-associated-lymphoid tissue (NALT) and the female 
genital tract in terms of homing determinants for primed B cells could explain why 
particularly high levels of specific IgA and IgG antibodies were found in cervico- vaginal 
secretions of mice after nasal immunization with transgenic live attenuated Mycobacterium 
bovis as an immunogen vector (Langermann et al, 1994), recombinant adenovirus vector 
expressing herpes simplex glycoprotein B (Gallichan and Rosenthal, 1996), an HIV 
peptide vaccine candidate (Staats et al., 1996), or group B streptococci (Hordnes et al, 
1997). Similar results have been obtained in Rhesus monkeys (Russell et al., 1996). A 
more recent study compared intranasal and intravaginal routes of immunisation in mice 
with a protein antigen coupled to cholera toxin B subunit. Mice immunised intranasally 
developed substantially stronger vaginal IgA and IgG and serum IgA and IgG antibodies 
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than those immunised intravaginally (Russell, 2002). In addition, the nasal route is 
generally found to be efficient for stimulation of systemic immunity and serum-derived 
antibodies appear to be of considerable importance in female genital secretions 
(Brandtzaeg, 1997). Based on the promising results obtained in mice, similar studies on the 
immunogenicity of intranasally applied outer membrane vesicles (OMVs) prepared from 
group B meningococci have been initiated in humans (Haneberg et al, 1997). A study by 
Johannsson et. al, (2001) involved vaccinating human volunteers nasally or vaginally 
with the model mucosal antigen cholera toxin B subunit. The study concluded that a 
combination of nasal and vaginal vaccination might be the best vaccination strategy for 
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ure 4. Model for homing pathways of primed lymphoid cells from inductive sites 
to effector sites (Brandtzaeg, 1997). 
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There is growing interest in development of vaccine strategies for induction or 
enhancement of local mucosal immune protection against sexually transmitted diseases 
(STDs) including HIV (Miller et al., 1992). Evaluation of anti-STD vaccines requires 
quantitative information about specific antibody concentrations in female genital 
secretions. The most convenient and widely used method for collection of these secretions 
is cervical-vaginal lavage (Belec et ah, 1995b), but lavage inevitably involves 
unpredictable dilution of secretions and this may render antibody concentrations too low to 
be detected by available assays. 
This study aims to assess humoral immunity using a site specific method for collection of 
vaginal secretions with minimal dilution. Such information will be important for 
establishing precise correlates of mucosal protection against specific STDs and for 
evaluating the potential protective abilities for candidate vaccines. In addition, antibody 
responses in both pregnant and non-pregnant females will be assessed and compared to 
better understand their differences in immune responses if any. The benefits would be dual: 
not only could the infection rate and subsequent morbidity and mortality in newborns be 
decreased but it may be possible to reduce the rampant spread of STIs through 
immunisation programs in the ensuing future. 
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CHAPTER THREE 
3.0 MATERIALS AND METHODS 
AIMS 
• To assess humoral immunity in the vaginal mucosa in pregnant and non-pregnant 
females using cervico- vaginal secretions from tampon samples. 
• To determine the difference, if any, between the systemic humoral response (using 
blood samples) and the results from cervico- vaginal secretions. 
OBJECTIVES 
• To extract protein from tampon samples. 
• To determine total protein concentration using BIORAD. 
• To quantitate immunoglobulins using ELISA. 
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3.1 Study Participants 
Ethical approval was obtained from the University Research Ethics Committee, Ref 
H123/00. Patients were recruited once consent was given and specimens were collected 
between February and September 2001. Subjects were divided into four groups i.e. non-
pregnant healthy women, pregnant healthy women, pregnant women with an STD and non-
pregnant women with an STD. Those without an STD were recruited from the third year 
medical students at the Nelson R. Mandela School of Medicine. The pregnant women with 
and without an STD were recruited from the Kwamsane Antenatal Clinic. Those non-
pregnant women with an STD were recruited from the Prince Cyrril Zulu Communicable 
Disease clinic in Warwick Avenue, Durban. 
3.1.1 Inclusion criteria 
For the two STD groups, all non-pregnant and pregnant women presenting with an STD 
were recruited. Thereafter, a routine STD workup determined if these women qualified for 
the study. Women recruited with an STD had to be positive for at least one of the 
following pathogens: Chlamydia trachomatis, Neisseria gonorrhea, Trichomonas 
vaginalis, or bacterial vaginosis. Pregnant women were recruited regardless of gestational 
age. 
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3.1.2 Exclusion Criteria 
All non-pregnant women in the study were not on any form of contraceptives. Women who 
were menstruating were not included in the study. 
3.1.3 Sample Size 
For each group there were 45 women recruited. However after STI testing, some women 
had to be regrouped which changed the sample size for each group. The sample size for 
each group was as follows: 
i non-pregnant, non- STD: 22 
ii non-pregnant, with STD: 60 
iii pregnant, non-STD: 22 
iv pregnant, with STD: 65 
3.2 Collection of Secretions 
The collection of secretions was done using commercially available tampons (Kotex). The 
tampons were self-administered, and remained in the vagina for 15 minutes after the 
patient had inserted the tampon. Once the tampon had been removed it was placed in 10 ml 
of phosphate buffered saline (PBS) (Appendix One), pH 7.4. Specimens were transported 
on ice and were stored at 4°C. The storage period did not exceed 24 hrs. 
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The vaginal secretions were squeezed from the tampon using autoclaved wooden tongue 
depressors. The PBS containing the secretions was aliqouted into 2 ml eppendorf tubes and 
stored at -20°C. The vaginal fluid was used in further tests as follows: 
i Four mis was aliquoted for use in the BD Probetech method. This method is used to 
detect Chlamydia trachomatis and Neisseria gonnorrhea and uses Strand 
Displacement Amplification (SDA) technology for direct, qualitative detection. The 
assay is based on the simultaneous amplification and detection of target DNA using 
amplification primers and a fluorescent labeled detector probe. The method 
followed was as for manufacturers instructions. 
ii One ml was aliquoted for an in- house PCR use to detect Trichomonas vaginalis. 
Primers were specific for a family of repeats that yielded a 413 bp product that was 
detected by gel electrophoresis, 
iii One ml for protein extraction (method below), 
iv a drop of fluid for a slide for BV detection. A routine Gram stain was performed for 
BV detection and diagnosis was based on Nugent's criteria (Nugent et. ah, 1991). 
Nugent's scoring system is as follows: 
0-3 : negative 
4-6: intermediate 
7-10 : positive 
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3.3 Extraction of protein from vaginal fluid 
Proteins were extracted using the method described by Quesnel et.al (1997). The thawed 
specimen was vortexed following which 50ul of specimen was used for extraction. Before 
protein extraction, 300ul of PBS containing protease inhibitors (0.2 mM 4-(2-aminoethyl)-
benzenesulfonylfluoride {Sigma, Germany}, 10 uM leupeptin {Sigma, Germany}, 1 |ig/ml 
aprotinin {Sigma, Germany} and 3.25 uM bestatin {Sigma, Germany}) was added in each 
2 ml eppendorf tube. Protein was allowed to precipitate for 30 min on ice (vortexed 3 or 4 
times). Tubes were then centrifuged at 16000 X g (9000 rpm) for 10 min at 4°C. To avoid 
protein reabsorption, supernatants were removed immediately after the spin. 
3.4 Total Protein Determination 
A 96 well microtitre plate (Costar, Corning Incorporated, New York) was used for this 
assay. The Bio-Rad Protein Assay was used in which the standard was y-globulin (Bio-
Rad, Germany) in two- fold serial dilutions to yield a standard curve. Ten ul of each 
standard and specimen solution was pipetted in duplicate into separate microtitre plate 
wells. The kit contained a dye reagent concentrate (Bio-Rad, Germany), which was added 
to each well (200ul). The assay is based on the observation that the absorbance maximum 
for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 run 
when binding to protein occurs. The plates were incubated at room temperature for at least 
five minutes. Absorbance was read at 595nm on the Anthos 2000 plate reader. For each 
specimen the absorbance reading was plotted on the standard curve (Fig 7) and the 
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concentration of protein was then extrapolated form the curve. The average concentration 
of the two samples was taken as a final result. 
3.5 Enzyme- Linked- Immunosorbent Assay (ELISA) 
The enzyme- linked- immunosorbent assay (ELISA) combines the specificity of antibodies 
with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an 
enzyme. 
The technique used was the two- antibody 'sandwich' ELISA. This ELISA is used to 
determine the antigen concentration in unknown samples provided a purified antigen 
standard is available. The change in enzyme activity as a result of the enzyme- Ab- Ag 
reaction is proportional to the concentration of the antigen and can be measured 
spectrophotometrically or with the naked eye. The ELISA applied was a double antibody 
sandwich method which was be used for the detection and measurement of 
immunoglobulins in sera as well as in vaginal secretions. (Fig 5). 
3.5.1 Optimisation 
Sterile tissue culture grade 96 well microtitre plates (Costar, corning Incorporated, New 
York) were used. To determine the optimal concentrations for the primary antibody and 
secondary antibody, titration dilution curves were done and those yielding the highest 
positive/ negative (P/N) ratio were chosen. 
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Plates were coated with a standard preparation of primary antibody concentrations starting 
with a 1: 125 dilution and thereafter a two- fold serial dilution was done for each primary 
antibody. For each dilution three rows were incubated with diluted serum as a positive 
(serum dilutions given below) and three rows were incubated with PBS as a negative. This 
allowed for the negatives and positives to be done in triplicate. Only one variable was 
changed at a time, in this case it was the primary antibody. The secondary antibody was 
added at a set concentration for each primary antibody concentration. For each assay, the 
primary antibody was diluted across the plate while one at a time the secondary antibody 
was changed starting from a 1:125 dilution. The average absorbance of the three positive 
rows was divided by the average absorbance of the three negative rows to give a P/N ratio 
(Figure 6). 
Primary antibody was diluted 1: 500 for goat anti- human IgG and IgA and 1:125 for goat 
anti-human IgM. For the secondary antibodies, goat anti- human IgA (Jackson 
ImmunoResearch, USA) was diluted 1:1000; goat anti-human IgG (Zymed, Germany) 
diluted 1:500 and mouse anti-human IgM (Zymed, Germany) diluted 1:250. All secondary 
antibodies were conjugated to alkaline phosphatase (AP). 
3.5.2 Construction of a Standard Curve 
Purified human IgG, IgA and IgM were used as standards (Biogenesis, UK). Each standard 
was serially diluted two- fold from a 10 ng/ml stock solution with a final dilution of 1.25 
ug/ml. Each standard was used to construct a standard curve from which immunoglobulin 
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concentration could be extrapolated (Fig 8). Standards were run with every plate to prevent 
inter-assay variability in results. Plate 2 shows how each plate was set up. 
3.5.3 Detection of Immunoglobulins 
3.5.3.1 Cervico- vaginal Secretions 
Plates were coated with lOOul of primary antibody, a goat antibody to human IgA or IgM 
or IgG (Zymed, Germany), and left overnight at 4°C in a humid container. All primary 
antibodies were diluted in a sodium carbonate coating buffer (Appendix One). The plates 
were then washed with PBS containing 0.05% Tween 20 (Sigma, Germany) to remove 
excess antibody and blotted on absorbent paper. To prevent non-specific binding, fetal calf 
serum (Sigma, Germany) was applied as a blocking agent to all wells for ten minutes at 
room temperature. The excess blocking agent was washed off and plates were blotted dry. 
Next 50ul of the specimen was added and incubated in a humid a container for 30 mins at 
37°C. Serial double dilutions of purified human IgA or IgG or IgM were added as 
standards (Biogenesis. England, UK). The excess specimen was washed off and the plates 
blotted dry. Thereafter 50ul of secondary antibody conjugated with alkaline phosphatase 
was added and incubated in a humid container for 30 mins at 37°C . All secondary 
antibodies were diluted in PBS. Plates were allowed to develop in the dark by addition of 
50ul of pNPP (para- nitrophenyl phosphate) (Zymed, Germany) substrate. A lOOul of a 3M 
sodium hydroxide (NaOH) solution was added to stop the reaction and optical densities 
were read at 405 nm with the Anthos 2000 plate reader. Immunoglobulin concentrations 
were determined by reference to the standard curves. Each plate had a negative control 
using PBS as a blank. All specimens were assayed in duplicate. 
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3.5.3.2 Serum Specimens 
All serum specimens had to be diluted to obtain a ~3-5 ug/ml range. Sera has a very large 
concentration of immunoglobulins and it is estimated that (Rassenti L. Z and Kipps T. J, 
1997): 
IgG has 8-16 mg/ml 
IgM has 1.4 - 4 mg/ml 
IgA has 0.5-2 mg/ml 
Therefore sera were diluted 1: 3000 for IgG, and 1: 250 for both IgM and IgA. 
Determinations of immunoglobulin concentrations were performed as for vaginal fluid. 
3.6 Statistical Methods 
A statistician used medians and ranges to summarise the data. The Wilcoxon Rank sum 
test was used to compare groups. A nonparametric measure was used because the 
assumption of normality was violated and could not be corrected by a transformation. 
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6. Calculation of P/N ratio for immunoglobulins e.g. IgA to determine coating 
antibody concentration. 
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Standard Curve(BIORAD ASSAY) 
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Figure 7. Standard curve plotted using y-globulin as standard. Optical density 
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4.1 Analysis of Immunoglobulins 
For all immunoglobulins, values were expressed as a ratio of the average quantitative ELISA 
result for each immunoglobulin over the patient's average total protein content. This ensured a 
standardised approach to exclude variable dilution factors of cervico- vaginal secretions. 
Results presented in the tables in this chapter are the median ratios for each group. 
The IgM levels in the cervico- vaginal secretions were very low and in many specimens 
undetectable. These low levels are not thought to be due to a technical problem given the fact 
that for every IgM ELISA the positive and negative controls ran optimally. As a result of these 
low levels, the median values for IgM in cervico- vaginal secretions were zero. However, the 
maximum absolute values (not as a ratio) for IgM in vaginal secretions were looked at in each 
group instead of the median. This is not a true statistical result but gives an idea of what an 
IgM response might be in the presence of a more sensitive test. 
4.2 Prevalence of STIs and BV 
Table I shows the prevalence of sexually transmitted infections diagnosed in the ANC and 
STD clinic attendees as well as in the control group. The overall prevalence of STIs and BV in 
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the control group that perceived themselves as not having a genital tract infection was 51.1%. 
None of them was pregnant. This STI prevalence was significantly higher in the STD clinic 
attendees. The ANC attendees showed a prevalence of 71% (p=0.04). 
In the analysis of the immune response parameters, women originally enrolled as controls but 
with an STI or BV were added to the non-pregnant group with infection. Table II shows the 
distribution of causes of discharge in the two final groups with infection. When women with 
BV were excluded, 56 % women had a single infection and 2.4 % a mixed infection. 
Trichomoniasis was significantly more prevalent in the pregnant as compared to the non-
pregnant women (p=0.0009) while gonorrhoea was seen with higher frequency in the non-
pregnant group (p=0.01). Chlamydia infections had a similar prevalence in both groups. BV 
prevalence was similar in both pregnant and non- pregnant women, however the pregnant 
women were more likely to have BV associated with another pathogen, in particular T. 
vaginalis. 
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Table I: Sexually transmitted pathogens and bacterial vaginosis in STD and ANC clinic 
attendees and controls. 
Number (%) with: 
Controls (n=45) 
STD clinic attendees (n=45) 


















Table II: Causes of vaginal discharge in pregnant and non- pregnant women. 




N. gonorrhoeae + 
C. trachomatis 
N. gonorrhoeae + T. vaginalis 
C. trachomatis + T. vaginalis 
Bacterial vaginosis (BV) 



































was significant in all three groups. The increase in IgM levels was seen in women with BV 
and in women with multiple STIs. The highest increase in IgM occurred in women with BV 
only. 
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Table III: Immunoglobulin ratios in non- pregnant women with a sexually transmitted 
infection and the control group. 



























* values given are maximum levels of IgM in each group and not median ratios. 
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Table IVa: Ig/ protein ratios in serum of women with single and multiple STIs and 
bacterial vaginosis. 
Median (range) of Ig/ protein ratio: 
Control group (n=44) 
Women with a single STI (n=22) 
Women with multiple STIs (n=48) 
















Table IVb: Ig/ protein ratios in cervico- vaginal secretions in women with single and 
multiple STIs and bacterial vaginosis. 
Median (range) of Ig/ protein ratio: 
Control Group (n=44) 
Women with a single STI (n=22) 
Women with multiple STIs (n=48) 
















* values given are maximum levels of IgM in each group and not median ratios. 
54 
4.5 Immunoglobulin ratios in women with N.gonorrhoeae and C. trachomatis 
infection versus those with trichomoniasis and BV 
To explore whether there is a difference in humoral immune response if the infection 
originates in the cervix or the vagina, a comparison was made between immunoglobulin ratios 
in women with N. gonorrhoeae or C. trachomatis infection and those with trichomoniasis and 
BV. When compared to healthy women, serum immunoglobulins showed no change in the 
presence of cervical pathogens. However, serum IgG (p=0.04) and IgA (p<0.0001) were 
significantly increased in the presence of vaginal pathogens (Table Va). Similarly, in cervical 
secretions, cervical pathogens do not alter immunoglobulin ratios. IgG (p=0.0002) and IgA 
(p<0.0001), in the presence of a vaginal pathogen, is significantly reduced when compared to 
healthy women. IgM shows an increase but this was not significant. 
When cervical pathogens were compared with vaginal pathogens, serum immunoglobulins 
showed no change. However, in cervico- vaginal secretions, IgG (p=0.008) and IgA (p=0.005) 
are significantly reduced in the presence of vaginal pathogens. IgM shows a higher increase in 
the presence of a vaginal pathogen but this was not significant. 
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Table Va: Immunoglobulin ratios (serum) in women with N. gonorrhoeae and/ or C. 
trachomatis infection versus those with T. vaginalis and/ or BV. 
Median (range) of Ig/protein ratio 
Control group (n=44) 
Women with N. gonorrhoeae 1 
C. trachomatis (n=8) 














Table Vb: Immunoglobulin ratios (cervico- vaginal secretions) in women with N. 
gonorrhoeae and/ or C. trachomatis infection versus those with T. vaginalis 
and/ or BV. 
Median (range) of Ig/protein ratios: 
Control group (n=44) 
Women with N. gonorrhoeae/ 
C. trachomatis (n=8) 














* values given are maximum levels of IgM in each group and not median ratios, 
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4.6 Immunoglobulin ratios in pregnancy 
In the absence of one of the causes of abnormal genital discharge, serum immunoglobulins 
during pregnancy showed no change but the cervico- vaginal secretions showed a significant 
decrease in IgA levels in the pregnant non-STD women (Table Via; p= 0.003). The trend 
observed in IgM was similar, with lower values in the vaginal secretions of pregnant women 
(Table VI). 
A change in immunoglobulins in pregnant women with an STD was seen when the non-
pregnant women with an STD were compared to the pregnant women with an STD. In serum 
the IgG and IgA were significantly increased in the non-pregnant STD group (Table VIb; p 
<0.001 and p= 0.02 respectively). The vaginal secretions showed the opposite with a 
significantly increased IgG in pregnant women with an STD (Table VI; p= 0.04). The 
increased IgG was still, however lower than the control group. 
Differences among pregnant women were determined by looking at pregnant women with an 
STD compared with pregnant women without an STD. IgA, in serum, was increased in 
pregnant women with an STD (Tale VI; p= 0.009; Fig 10). In vaginal secretions, the opposite 
was seen. IgA was significantly decreased in pregnant women with an STD (Table Vic; p= 
0.001; Fig 13) but IgM showed a trend in the opposite direction (Fig 14). Pregnant women 
with an STD have much higher IgM levels than pregnant women without an STD (Table Vic). 
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Table VIb: Immunoglobulin ratios in pregnant and non- pregnant women with STIs. 

























* values given are maximum levels of IgM in each group and not median ratios. 
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Table Vic: Immunoglobulin ratios in pregnant women with and without STIs. 


























* values given are maximum levels of IgM in each group and not median ratios. 
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4.7 Extreme Values in Serum and Vaginal Secretions 
Extreme values were observed for two subjects. In one subject's serum sample, all 
immunoglobulin levels were extremely high. This subject was positive for only one STI 
pathogen, N. gonorrhoea, and was not pregnant. 
The other subject had extreme values for IgG and IgA in her vaginal secretions. This subject 
was positive only for BV and was pregnant. 
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STD neg STD pos* STD neg STD pos 
not pregnant — 
Figure 9. Serum ratios for IgG for each group. 
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Figure 10. Serum ratios for IgA for each group. 
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Figure 11. Serum ratios for IgM for each group. 
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Figure 12. IgG ratios in cervico- vaginal secretions for 
each group. 
















Figure 13. IgA ratios in cervico- vaginal secretions for each 
group. 
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All women recruited for the study were in the age group ranging from 20-45. Pregnancy 
testing was not performed for the control group, however there were no births in this group 
during the study period thereby ruling out early gestation. The majority of these women 
were familiar with the use of a tampon and those who were not were given assistance. For 
this study it was not necessary to obtain vaginal secretions from a specific site in the 
vagina but rather to collect all secretions present in the vagina. Previous studies have 
described different methods for the collection of vaginal secretions e.g. cervical- vaginal 
lavage (Belec et al, 1995), Sno-strips and wicks (Quesnel et al., 1997), and the use of a 
plastic transfer pipette ( Kutteh et al, 1996). However, lavage involves considerable 
dilution, the Sno-strips are difficult to handle due to their pliability, wicks can be 
contaminated by blood staining and the pipette method is only feasible during days of the 
cycle near ovulation. All secretions obtained via tampon were free from blood staining, 
easy to use and subject to a total protein determination to standardise results. 
Specimens were collected from women at any time during their cycle except when they 
were menstruating. Wide variations seen in the immunoglobulin values in the vaginal 
secretions among women in the same group can be attributed to this fact. It has been 
observed that oestrogen and progesterone have an effect on vaginal immunity 
(Schumacher, 1980). Therefore variations in the oestrogen and progesterone levels during 
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the menstrual cycle have an impact on immunoglobulin levels. A recent study also reported 
large individual variations in immunoglobulin levels (Bard et ah, 2002). 
There are no obvious explanations for the two subjects with extreme values in their serum 
and cervico- vaginal secretions. It could be that their infections were very severe and 
caused a pronounced immune response. Alternatively, they could have been co-infected 
with some other infection other than those tested for. 
When comparing the IgA and IgG levels in control groups it is found that IgA is 
predominant in cervico- vaginal secretions and IgG is predominant in serum. There have 
been variable reports about the presence of various immunoglobulin subclasses in human 
female genital secretions. Waldman et. ah (1971) found IgA to be predominant while 
Hocini et ah (1995) reported a predominance of IgG in normal vaginal fluid. Such 
discrepancies probably reflect both differences in the applied sampling method and 
individual variables such as age and phase of menstrual cycle. 
All groups, when compared to the control group, have significantly lower IgA levels in 
cervico- vaginal secretions. For IgA, both pregnancy and the presence of an STI, lower 
IgA levels. In pregnant women IgA levels are further lowered with the presence of a STI. 
In serum IgA behaves similarly to IgG and both pregnant and non-pregnant women with an 
STI have significantly higher Ab levels. This increase is due solely to the presence of an 
STI. 
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Women with an STI show significantly decreased IgG in cervico- vaginal secretions with 
this effect being greater in non- pregnant women. In the absence of an STI there is no 
significant difference between non-pregnant and pregnant women. However, pregnancy 
does cause a slightly lower IgG level. It appears the STI is the significant cause for the 
decrease and that pregnancy has some effect but not significantly so. The opposite 
response is seen in serum. IgG is increased in the presence of an STI. This is true only for 
the non-pregnant women with an STI. Pregnancy, regardless of an STI, has no effect on 
IgG in serum. 
IgM behaves differently to IgG and IgA in cervico- vaginal secretions. Although IgM in 
the cervico- vaginal secretions is mostly too low to be detectable, the highest absolute 
values are in those women with an STI (pregnant and non- pregnant). There appears to be 
an effect of pregnancy. Detectable IgM levels shows lower values in pregnant women 
without an STI, however, in the presence of an STI both pregnant and non-pregnant 
women have much higher values. This increase is greater in non-pregnant women. Serum 
IgM levels shows no change regardless of pregnancy or the presence of an STI. 
In serum, immunoglobulin levels are unaltered in women regardless of pregnancy if they 
are free of an STI. In keeping with other studies it is shown that pregnancy has no effect on 
serum immunoglobulins. A study by Xusheng Lu et al. (1999) showed that in rhesus 
macaques, ovarian hormones that drive the menstrual cycle do not affect systemic 
immunoglobulin or antibody levels. 
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However, in the presence of an STI, IgA and IgG are increased. It was to be expected that 
serum imunoglobulin levels would be raised in non-pregnant women with an STI. This is 
indicative of an immune response. However, it is interesting to note that serum IgM levels 
were unchanged. This could be attributed to the nature of the STI in those women infected. 
If the infection was not recent then it follows that secondary immunity has developed 
bringing about the increased IgG values. 
The opposite of the systemic response is seen to take place in the cervico- vaginal 
secretions. IgA is decreased in all groups when compared to the control group and IgG is 
decreased in the STI groups. This is contrary to what has been reported in previous studies 
where colonisation with a bacteria has resulted in an increase in IgG and IgA with either 
IgG or IgA predominating. Chlamydia trachomatis has been reported to act particularly 
stimulatory on the appearance of slgA in cervicovaginal secretions (Heisterberg et. al. 
1987). 
It is quite clear that pregnancy does have an effect on immunoglobulin levels. This is 
especially so for IgA in the cervico- vaginal secretions. One possible explanation for the 
decreased IgA and slightly decreased IgG is the effect of the reproductive hormones. 
Oestrous-cycle-dependent changes have been documented in the immune cell population 
of the rat uterus and vagina (Kaushic et al., 1998). It has been reported that the secretion of 
IgG and IgA into vaginal fluids was reduced in the presence of high levels of oestrogen 
(Schumacher, 1980; Wira et al, 1994). The decrease in IgA in vaginal secretions during 
pregnancy could be caused by a shift in immunity away from the vagina towards the 
uterus. Oestrogen has a stimulatory effect on immunoglobulins in the uterus (Wira et al, 
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1994) and the opposite effect in the vagina (Wira et al, 1994). Therefore, the decrease in 
IgA can be explained by the hormonal effect of pregnancy. 
However, a recent study looking at the number and distribution of immune cells in the 
cervico- vaginal mucosa of rhesus macaques, showed that steroid hormones do not 
influence genital mucosal immunity by changing the number or distribution of immune 
cells in the lower reproductive tract (Ma et al, 2001). This would explain why there is no 
significant effect of pregnancy on IgG and IgM in vaginal secretions. However it does not 
explain the exception in the significantly decreased IgA levels during pregnancy. Whether 
pregnancy influences IgA solely, and how, is unclear. 
An interesting observation is the trend of higher IgM levels in the STI groups in cervico-
vaginal secretions. It seems that IgM offers protection against invading pathogens at the 
site of infection. One hypothesis could be that IgM offers a primary immune response with 
antibodies arising from the vaginal mucosa itself. Thereafter secondary immunity is more a 
systemic response and hence the decreased IgG and IgA in the cervico- vaginal secretions 
but elevated levels in the serum. This primary immune response might explain why IgM 
levels are so low in the cervico- vaginal secretions since a primary immune response does 
not last long, a few days at most. If this is so, then IgM is being cleared and is therefore not 
easily detectable. 
There has been much debate about the derivation of vaginal antibodies. It is believed that 
through functional compartmentalization of its afferent and efferent limbs, MALT is to a 
significant extent independent of the systemic immune apparatus. In humans the fallopian 
tubes, cervix and the vagina have been reported to contain sub-epithelial immunoglobulin-
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producing immunocytes (Kutteh et ai, 1988). This study shows that while there is an 
increase in immunoglobulins in serum, the opposite is seen in vaginal secretions. This 
supports the theory of local antibody production. Here, an increase in IgG and IgA in 
serum does not cause any increase in the cervico- vaginal secretions significant or 
otherwise. The higher IgM levels in the cervico- vaginal secretions of women with an STI 
would therefore be locally produced since there is no change seen in serum IgM. 
Bacterial vaginosis is the most common cause of vaginal discharge, although its 
classification as a true STI pathogen is unclear. It was necessary to determine the role, if 
any, of BV on immunoglobulin levels. The above results show that BV does play a very 
significant role in serum and vaginal immunoglobulin levels. 
It is shown that BV has an interesting effect on IgG and IgM. In serum IgG was 
significantly increased only in the presence of BV and multiple infections. Single 
infections without BV did not alter IgG levels but did alter IgA levels. IgM levels remained 
unchanged regardless of the presence of an infection. 
In cervico- vaginal secretions, IgG was significantly decreased, again, only in the presence 
of BV and multiple infections. The highest increase in IgM was in the presence of BV. 
BV has a definite effect on IgG. Why this is so is unclear but it would be interesting to 
explore the pathophysiology in relation to this immunoglobulin. It has been reported that 
the presence of sialidase, a hydrolytic enzyme produced by BV- associated bacteria, has an 
effect on anti- Gardnerella vaginalis IgA (Cauci et ah, 2002). Sialidase cleaves the 
terminal sialic acid from glycoproteins, including immunoglobulins and especially IgA. 
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Thus, sialidases may potentially hamper the local mucosal immune response. This could 
explain the decreased IgA and IgG levels found in cervico- vaginal fluid in the presence of 
an STI, especially BV. Why this effect cannot be seen for IgM is unclear. It could be that 
IgM is structurally different to IgA and IgG. IgM is bigger than the other two 
immunoglobulins and this could offer some protection against hydrolytic activity. 
Although BV is seen to have a significant effect on all three immunolobulins, other single 
infections also show a similar pattern. It is hard to determine whether the stage of infection 
in women with other single infections affects the significance of the results. Especially 
when considering an STI like syphilis which has various stages of infection. However, 
whether BV alone has an effect on immunoglobulin levels is unclear given that sample size 
would be too small to make a definite conclusion. It is clear though that all the STI 
pathogens follow a similar trend and each pathogen has an impact on immunoglobulin 
levels. 
The analysis of cervical and vaginal pathogens yielded interesting results. It appeared, 
from the numbers per group, that the tampon specimen picked up mainly vaginal 
pathogens. When compared to healthy women, vaginal pathogens, unlike cervical 
pathogens, elicited an immune response in serum. It is interesting that only the vaginal 
pathogens alter serum immunoglobulins. Vaginal pathogens lowers IgG and IgA levels 
much more than cervical pathogens in cervico-vaginal secretions. This effect further 
supports the theory of compartmentalisation. The higher IgM levels in the presence of 
vaginal pathogens helps prove this too. 
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Overall the results do not suggest that pregnancy has some effect on immunoglobulin 
levels except for IgA in cervico vaginal secretions. Changes in immunoglobulin levels are 
seen regardless of pregnancy and are as a result of the presence of an STI. The only 
exception is seen in the significantly decreased vaginal IgA levels in pregnant women 
without an STI. Why the presence of an STI brings about a decrease in vaginal IgG and 
IgA is unclear. A primary IgM response is seen but thereafter what happens is unknown. 
The contrasting results in this study compared to other studies, especially with regard to 
cervico- vaginal immunoglobulin results, can be attributed to the type of pathogens studied 
and their affect on each other. Other studies have mainly looked at non- STI pathogens, 
predominantly streptococcus. The effect of the human immunodeficiency virus (HIV) has 
not been accounted for. Women in this study were not divided into HIV groups so the 
effect of HIV is unknown. Whether the contrasting results can be attributed to the effects 
of HIV needs to be determined. How HIV alters the immune response, if at all, and 
especially its effect on STI pathogens is a possible avenue for further study. These inter-
relationships would provide a clearer picture of vaginal immunity especially considering 




The results presented above suggest a distinct immune response in the vaginal mucosa 
compared to a systemic response. STIs induce a normal systemic Ab response but a 
reversed IgG and IgA response at the mucosal level. While pregnancy does not alter 
systemic responses it does have an effect on mucosal immunity, predominantly IgA. 
The effect of BV also warrants further attention. It is clear that BV has a significant effect 
on mucosal immunity and considering its association with poor pregnancy outcome, 
further understanding of BV interactions at the mucosal level would be beneficial. 
Systemic and mucosal IgG and IgA responses to both STIs and BV showed opposite 
trends. This indicates a compartmentalised effect and might explain why organisms that 
cause STIs are such successful pathogens. 
The mucosal immune system should be most efficient in providing protection against 
pathogens and generating longer- lasting protection through using attenuated pathogens for 
vaccine purposes. This is the ultimate aim but it is necessary to first understand the effect 
of different pathogens on the mucosal immune system. Further studies assessing mucosal 
immunity in relation to pathogens and especially looking at the effect of HIV would 
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CHAPTER EIGHT 
0 Appendix One 
Coating Buffer, pH 9.6 
• Dissolve 2.93 g Sodium Hydrogen Carbonate (NaHC03; Merck, South Africa) in 
500 ml distilled water. 
• Add 1.59 g Sodium Carbonate Anhydrous (Na2C03; Merck, South Africa) and stir 
until dissolved. 
• Add 0.20 g Sodium Azide (NaN3; Sigma, Germany) and stir until dissolved. 
• Check pH and adjust with 5M Hydrochloric Acid (HCL; Sigma, Germany) if 
necessary. 
• Make up to one litre. 
• Expiry date is two weeks after preparation. Store at 4 - 8 °C. 
Phosphate Buffered Saline (PBS) 
• Dissolve 1 PBS tablet in 100 ml of distilled water. 
• Autoclave for 30 mins and store at 4 - 8 °C. 
